Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             378 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 CE1 COSTO-EFECTIVIDAD DE UNA INTERVENCIÃN ECO-SISTÃMICA PARA EL CONTROL DEL DENGUE EN GIRARDOT-COLOMBIA DESDE LA PERSPECTIVA DE LA SOCIEDAD Taborda, A.
 2019
 19 S p. S1
 artikel
2 CE3 ECONOMIC EVALUATION OF THE USE OF PRE-FILLED SYRINGE VERSUS MANUALLY FILLED SYRINGE PARAFLUSHING IN PATIENTS WITH CENTRAL VENOUS CATHETER IN THE PERSPECTIVE OF HEALTH CAREERS Gomes, M.
 2019
 19 S p. S1
 artikel
3 CE4 TRATAMIENTOS PARA LOS PACIENTES CON ESCLEROSIS MULTIPLE REMITENTE RECURRENTE CON ALTA ACTIVIDAD DE LA ENFERMEDAD: ANALISIS COSTO EFECTIVIDAD EN MEXICO Rubio Ponce, R.
 2019
 19 S p. S1
 artikel
4 CL2 EFFECTIVENESS OF TREATMENT WITH DIRECT-ACTING ANTIVIRALS IN THE COLOMBIAN POPULATION WITH CHRONIC HEPATITIS C Acuña Merchan, L.
 2019
 19 S p. S2
 artikel
5 CL3 ESTUDIO DE EVALUACIÃN ECONÃMICA DEL APÃSITO TRANSPARENTE IMPREGNADO CON CLORHEXIDINA, PARA LA FIJACIÃN DE CATÃTERES CENTRALES BAJO EL CONTEXTO DE LOS HOSPITALES PÃBLICOS DE REPáBLICA DOMINICANA: CASO HOSPITAL DOCENTE PADRE BILLINI, AÃO 2017. Carvajal Nunez, A.D.
 2019
 19 S p. S2
 artikel
6 CL1 PATIENT ACTIVATION MEASURE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ITS IMPORTANCE REGARDING EMPOWERMENT Arrighi, E.
 2019
 19 S p. S1
 artikel
7 CM1 EFECTIVIDAD Y SEGURIDAD DE LA RESECCIÃN MUCOSA ENDOSCÃPICA FRENTE A LA DISECCIÃN SUBMUCOSA EN PACIENTES CON CÃNCER GÃSTRICO TEMPRANO: REVISIÃN SISTEMÃTICA CON METANÃLISIS Posso, M.
 2019
 19 S p. S2
 artikel
8 CM2 REMOTE MONITORING AFTER THE IMPLANTATION OF A CARDIOVERTER-DEFIBRILLATOR: A SYSTEMATIC REVIEW AND META-ANALYSIS Lucchetta, R.C.
 2019
 19 S p. S2
 artikel
9 CM3 REVIS SISTEMÃTICAS DOS MODELOS DE ORGANIZAÇÃO DE SISTEMAS PÚBLICOS DE SAÚDE PARA O CUIDADO DA OBESIDADE INFANTIL E SUA EFETIVIDADE NO MUNDO Mosegui, G.
 2019
 19 S p. S2-S3
 artikel
10 CM4 TIME TO TREATMENT EFFECT, EVENT-FREE SURVIVAL, AND MOTOR MILESTONE ACHIEVEMENT IN TYPE I SPINAL MUSCULAR ATROPHY PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC (AVXS-101) OR NUSINERSEN CONTRASTED TO NATURAL HISTORY Dabbous, O.
 2019
 19 S p. S3
 artikel
11 CN4 ANÁLISIS DE COSTO-UTILIDAD E IMPACTO PRESUPUESTARIO DE LA ENZALUTAMIDA PARA EL TRATAMIENTO DEL CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN NO METASTÁSICO (CPRCNM) EN ARGENTINA Toro, W.
 2019
 19 S p. S4
 artikel
12 CN1 CALIDAD DE VIDA RELACIONADA A LA SALUD Y COSTOS DEL SISTEMA DE SALUD, POR PÉRDIDA DE PRODUCTIVIDAD Y OTROS DE PACIENTES CON DIAGNOSTICO DE CÁNCER DE MAMA EN AMÉRICA LATINA Y EL CARIBE: REVISIÓN SISTEMÁTICA Y META-ANALISIS Augustovski, F.
 2019
 19 S p. S3
 artikel
13 CN2 EVALUACIÓN DE COSTO-EFECTIVIDAD DE LA ENZALUTAMIDA (ENZA) FRENTE A LA ABIRATERONA (ABI) PARA EL TRATAMIENTO DE PACIENTES CON CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN METASTÁSICO (CPRCM) ANTES DEL USO DE DOCETAXEL EN EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS) Gay, J.G.
 2019
 19 S p. S3
 artikel
14 CN3 SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF COLORECTAL CANCER SCREENING STRATEGIES FOR THE EARLY DETECTION OF COLORECTAL CANCER IN THE GENERAL POPULATION Mendivil, J.
 2019
 19 S p. S3-S4
 artikel
15 CR3 COSTOS DIRECTOS Y CUMPLIMIENTO DE INDICADORES DE CONTROL METABOLICO EN PACIENTES CON DIABETES MELLITUS TIPO 2 EN UN HOSPITAL PUBLICO DE COLOMBIA Manrique Torres, G.A.
 2019
 19 S p. S4
 artikel
16 CR4 ESTIMATION OF THE ECONOMIC AND HEALTH EFFECTS OF CHRONIC KIDNEY DISEASE IN CHILEAN POPULATION OLDER THAN 60 YEARS OLD Rojas, R.
 2019
 19 S p. S5
 artikel
17 CR2 IMPACTO ECONOMICO DE CANCER DE MAMA Y SU TENDENCIA AL 2030 EN EL SISTEMA DE SALUD PUBLICO DEL PERU Gutierrez-Aguado, A.
 2019
 19 S p. S4
 artikel
18 CR1 LOS COSTOS INDIRECTOS DE LA MORTALIDAD MATERNA EN BRASIL: UN ESTUDIO DE COSTOS DE ENFERMEDADES Lynn, F.
 2019
 19 S p. S4
 artikel
19 CV1 CARDIOVASCULAR RISK IN DIABETES PATIENTS MONITORED BY A MOBILE PHONE APP HEALTH CARE PROGRAM IN BRAZIL Picoli, R.
 2019
 19 S p. S5
 artikel
20 CV3 COST-EFFECTIVENESS OF A COMPREHENSIVE INTERVENTION FOR HYPERTENSION CONTROL IN LOW-INCOME SETTINGS IN ARGENTINA: A MARKOV MODEL Shi, L.
 2019
 19 S p. S5
 artikel
21 CV4 EVALUACION DE LOS MOTIVOS DE LA OMISION DE RETIROS DE MEDICAMENTOS PENDIENTES EN LA OFICINA DE FARMACIA. POSIBLES SOLUCIONES Lalin, M.
 2019
 19 S p. S5-S6
 artikel
22 CV2 MODELO PREDICTIVO DEL RIESGO DE MUERTE EN PACIENTES DIABETICOS APLICADO EN UNA COMPAÑIA DE ASEGURAMIENTO EN SALUD DE COLOMBIA Garcia Rojas, D.
 2019
 19 S p. S5
 artikel
23 EP3 CARACTERIZACIÓN EPIDEMIOLÓGICA DE PACIENTES CON ARTRITIS REUMATOIDE ATENDIDOS EN SISTEMA GENERAL DE SEGURIDAD SOCIAL EN SALUD DE COLOMBIA. Fuentes, J.C.
 2019
 19 S p. S6
 artikel
24 EP4 HOW IS SELF-PERCEIVED HEALTH STATUS (EQ-5D) ASSOCIATED WITH SOCIOECONOMIC CONDITIONS IN 22 LATIN AMERICAN COUNTRIES? Cabieses, B.
 2019
 19 S p. S6
 artikel
25 EP2 PUBLIC HEALTH AND ECONOMIC IMPACT OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM FOR FEMALES AGED 9 YEARS IN EL SALVADOR Rendon, A.M.
 2019
 19 S p. S6
 artikel
26 EP1 SCHOOL ENVIRONMENT FACTORS ASSOCIATED WITH ADOLESCENTS BMI IN BRAZIL Balbinotto, G.
 2019
 19 S p. S6
 artikel
27 Financial Disclosure Information 2019
 19 S p. S86-S88
 artikel
28 HI4 ADHERENCE TO TREATMENT IS ASSOCIATED WITH GOOD CLINICAL RESULTS IN PATIENTS TREATED WITH BIOLOGICAL THERAPY IN A CENTER OF EXCELLENCE IN RHEUMATOID ARTHRITIS Santos-Moreno, P.
 2019
 19 S p. S7
 artikel
29 HI2 EVALUATION OF THE MEDICAL PROCEDURES ON AN ADMINISTRATIVE DATABASE TO IDENTIFY PATIENTS WITH SUSPECTED PRE-ECLAMPSIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM Ho, R.
 2019
 19 S p. S7
 artikel
30 HI3 EVIDENCIA DE LA VIDA REAL EN ARGENTINA: TRATAMIENTO DE PACIENTES CON HEPATITIS C EN EL SISTEMA DE TUTELAJE DE TECNOLOGIAS SANITARIAS EMERGENTES (STTSE) Denamiel, J.
 2019
 19 S p. S7
 artikel
31 HI1 PRELIMINARY COST ANALYSIS OF MISDIAGNOSIS OF RHEUMATOID ARTHRITIS Valencia, O.
 2019
 19 S p. S6-S7
 artikel
32 HT3 BASE DE COSTOS UNITARIOS EN SALUD EN ARGENTINA: UNA FUENTE DE INFORMACIÓN CONTINUAMENTE ACTUALIZADA PARA EVALUACIONES ECONOMICAS Y ANALISIS DE IMPACTO PRESUPUESTARIO EN UN SISTEMA DE SALUD FRAGMENTADO Palacios, A.
 2019
 19 S p. S8
 artikel
33 HT2 DISEÑO E IMPLEMENTACIÓN DE UN PROCESO DE INVOLUCRAMIENTO ACTIVO DE ACTORES RELEVANTES EN UNA AGENCIA DE EVALUACIÓN DE TECNOLOGÍAS SANITARIAS DE ARGENTINA Klappenbach, R.
 2019
 19 S p. S8
 artikel
34 HT4 EXPERIENCIAS INTERNACIONALES ACERCA DE LOS CRITERIOS DE DECISIÓN USADOS EN LA PRIORIZACIÓN DE LAS TECNOLOGÍAS DE SALUD Moreno-Calderón, A.
 2019
 19 S p. S8
 artikel
35 HT1 TRANSFERIBILIDAD DE LAS EVALUACIONES ECONOMICAS PARA LA TOMA DE DECISIONES: UNA REVISION DE REVISIONES SISTEMATICAS Mezones-Holguin, E.
 2019
 19 S p. S7-S8
 artikel
36 MT4 ANALISIS DE IMPACTO PRESUPUESTARIO SOBRE LA INCORPORACION DEL COCIENTE SFLT-1/PLGF PARA PREDECIR EL RIESGO DE PREECLAMPSIA EN LA COBERTURA DE LAS OBRAS SOCIALES NACIONALES DE ARGENTINA Garay, U.
 2019
 19 S p. S9
 artikel
37 MT1 ANÁLISIS COSTO-EFECTIVIDAD DE UN SISTEMA DE TROMBECTOMÍA REOLÍTICA PARA EL TRATAMIENTO DE LA ISQUEMIA AGUDA DE MIEMBROS INFERIORES EN ADULTOS MEXICANOS Cerecero-García, D.
 2019
 19 S p. S8-S9
 artikel
38 MT3 ICD THERAPY FOR SUDDEN CARDIAC ARREST PREVENTION IS POTENTIALLY COST-EFFECTIVE IN THE 1.5 PRIMARY PREVENTION POPULATION IN COLOMBIA: AN ECONOMIC EVALUATION OF THE IMPROVED SCA STUDY Higuera, L.
 2019
 19 S p. S9
 artikel
39 MT2 REMOTE MONITORING COMPARED TO CONVENTIONAL FOLLOW-UP FOR PATIENTS WITH HEART FAILURE USING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR: A BUDGET IMPACT ANALYSIS Lucchetta, R.C.
 2019
 19 S p. S9
 artikel
40 PAM4 ANALISE DOS CUSTOS DE TERAPIAS NUTRICIONAIS APOS ACOES DE AUDITORIA: UMA ANALISE DE DADOS DO MUNDO REAL Viana, A.
 2019
 19 S p. S10
 artikel
41 PAM5 AVALIAÇÃO DO USO DA OZONIOTERAPIA EM PACIENTES COM DOR LOMBAR: UM ESTUDO DE METANALISE Teixeira, L.A.A.
 2019
 19 S p. S10
 artikel
42 PAM6 COMPLEMENTARY AND INTEGRATIVE THERAPIES IN BRAZIL'S UNIFIED HEALTHCARE SYSTEM (SUS) IN 2017: AN UNDERREPORTING CASE Alencar Junior, F.O.
 2019
 19 S p. S10-S11
 artikel
43 PAM3 COST MINIMIZATION BETWEEN READY TO USE OLIVE OIL-BASED PARENTERAL NUTRITION AND SUBROGATE COMPOUNDED PARENTERAL NUTRITION, ANALYSIS FROM A HIGH SPECIALITY REGIONAL MEXICAN HOSPITAL. Jiménez Aranda, P.
 2019
 19 S p. S10
 artikel
44 PAM2 GESTION DE SOPORTE NUTRICIONAL EN CUIDADOS INTENSIVOS Fernandez Mercado, J.C.
 2019
 19 S p. S9-S10
 artikel
45 PAM1 RESULTADOS DE LA IMPLEMENTACION DEL MODELO DE SOPORTE NUTRICIONAL EN LOS NIVELES HOSPITALARIO Y DOMICILIARIO Fernandez Mercado, J.C.
 2019
 19 S p. S9
 artikel
46 PBI3 ANÁLISIS DEL COSTO POR RESPONDEDOR DE SECUKINUMAB VS INFLIXIMAB Y ETANERCEPT PARA EL TRATAMIENTO DE LA ARTRITIS PSORIÁSICA DESDE UNA PERSPECTIVA ECUATORIANA Afanador Echeverri, G.F.
 2019
 19 S p. S11
 artikel
47 PBI7 CASE STUDY: ECONOMICAL ANALYSIS OF WASTE IN BIOLOGICAL PRODUCTS IN AN INSTITUTION IN COLOMBIA Sarria, A.
 2019
 19 S p. S12
 artikel
48 PBI4 COMPORTAMIENTO DE USO DE TERAPIA BIOLÓGICA Y COSTOS ASOCIADOS DE UN PROGRAMA DE ATENCIÓN EN PACIENTES CON DIAGNASTICO DE ARTRITIS REUMATOIDE EN COLOMBIA Hoyos, F.
 2019
 19 S p. S11
 artikel
49 PBI5 COST OF ADVERSE EVENTS ASSOCIATED WITH TREATMENT WITH BIOLOGICAL DRUGS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN ARGENTINA Alfie, V.
 2019
 19 S p. S11-S12
 artikel
50 PBI11 ESTUDIOS DE SINTESIS Y TOMA DE DECISIONES: A PROPOSITO DE LA CONTINUACION DEL TRATAMIENTO CON UN BIOSIMILAR EN PACIENTES QUE RECIBEN INFLIXIMAB EN EL SEGURO SOCIAL EN SALUD EN PERU Mezones-Holguin, E.
 2019
 19 S p. S13
 artikel
51 PBI6 EVALUATION OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN COLOMBIA: A COST PER RESPONDER ANALYSIS (CPR) Gil-Rojas, Y.
 2019
 19 S p. S12
 artikel
52 PBI9 MEDICATION USE AND REASONS FOR SWITCHING BIOLOGIC THERAPY IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: FINDINGS FROM A GLOBAL SURVEY Hunter, T.
 2019
 19 S p. S12
 artikel
53 PBI8 O IMPACTO ECONOMICO DO PROCESSO DE VERTICALIZACAO NO USO DE IMUNOBIOLOGICOS INDICADOS PARA DOENCA DE CHRON EM UMA OPERADORA DE PLANOS DE SAUDE Vieira, J.B.
 2019
 19 S p. S12
 artikel
54 PBI10 REAL WORLD SWITCHING PATTERNS OF ETANERCEPT ORIGINAL AND BIOSIMILAR IN GERMANY Alten, R.
 2019
 19 S p. S12-S13
 artikel
55 PBI1 THE VALUE OF ONASEMNOGENE ABEPARVOVEC (AVXS-101) AS A COST-EFFECTIVE GENE REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 IN IMPROVING SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND MOTOR FUNCTION Malone, D.C.
 2019
 19 S p. S11
 artikel
56 PCN39 ACCESS TO MEDICAL INTERVENTIONS IN BRAZIL: THE ROLE OF CLINICAL RESEARCH AND OF HEALTH JUDICIALIZATION Pereira da Veiga, C.
 2019
 19 S p. S20
 artikel
57 PCN68 ADVANCED NON-SMALL CELL LUNG CANCER IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL: RETROSPECTIVE COHORT STUDY Ferreira, C.G.
 2019
 19 S p. S25
 artikel
58 PCN64 ANALISIS COMPARATIVO DE LOS COSTOS DEL PACIENTE CON CARCINOMA HEPATOCELULAR ENTRE REGIMENES CONTRIBUTIVO Y SUBSIDIADO Romero Prada, M.
 2019
 19 S p. S24-S25
 artikel
59 PCN61 ANALISIS DE CORRELACION DE EQ5D 3L Y EORTC QLQ C30 EN POBLACION COLOMBIANA CON CANCER Romero Prada, M.
 2019
 19 S p. S24
 artikel
60 PCN67 ANALYSIS OF TREATMENT PATTERNS FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM IN DIFFERENT GEOGRAPHIC REGIONS OF BRAZIL Britto, G.
 2019
 19 S p. S25
 artikel
61 PCN19 ANÃLISE DO CUSTO-EFETIVIDADE DA RADIOTERAPIA COM INTENSIDADE MODULADA NO TRATAMENTO DO CÃNCER DE PRÃSTATA LOCALIZADO Fernandez, C.R.
 2019
 19 S p. S16
 artikel
62 PCN65 ANÃLISIS COMPARATIVO DE CUSTOS DE PACIENTES DE CÃNCER POR REGIÃO GEOGRÃFICA Romero Prada, M.
 2019
 19 S p. S25
 artikel
63 PCN9 ANÁLISIS DE IMPACTO PRESUPUESTAL DE LA DETECCIÓN TEMPRANA DEL CÁNCER DE CUELLO UTERINO EN MUJERES DE 30 A 65 AÑOS MEDIANTE TAMIZACIÓN CON TEST DE VPH Y GENOTIPIFICACIÓN FRENTE CITOLOGÍA CONVENCIONAL, EN COLOMBIA Amezquita, D.
 2019
 19 S p. S14
 artikel
64 PCN18 ANTINEOPLASICOS ORAIS NA PRIMEIRA LINHA DE TRATAMENTO DE LEUCEMIA MIELOIDE CRONICA: UMA ANALISE DE CUSTO Albuquerque, I.
 2019
 19 S p. S16
 artikel
65 PCN46 ASSESSING THE QUALITY OF THE EVIDENCE OF NIVOLUMAB ACCORDING TO THE HTA REQUIREMENT IN ARGENTINA Glancszpigel, M.
 2019
 19 S p. S22
 artikel
66 PCN3 BRAND-BRAND ONCOLOGY COMBINATIONS: HURDLES AND IMPLICATIONS Boers Trilles, V.
 2019
 19 S p. S13-S14
 artikel
67 PCN27 BUDGET IMPACT ANALYSIS OF MIDOSTAURIN IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA Espinola, N.
 2019
 19 S p. S18
 artikel
68 PCN35 BURDEN OF DISEASE FOR ADVANCED BREAST CANCER IN BRAZIL Novick, D.
 2019
 19 S p. S19-S20
 artikel
69 PCN31 BURDEN OF DISEASE FOR ADVANCED BREAST CANCER IN MEXICO Novick, D.
 2019
 19 S p. S19
 artikel
70 PCN55 CALIDAD DE VIDA RELACIONADA CON LA SALUD Y DESENLACES PERCIBIDOS POR PACIENTES CON CANCER DE MAMA EN COLOMBIA Romero Prada, M.
 2019
 19 S p. S23
 artikel
71 PCN58 CANCER PATIENTS PREFER REPORTING SYMPTOMS IN DAILY ELECTRONIC DIARIES AT HOME Yamamoto, R.T.
 2019
 19 S p. S23
 artikel
72 PCN45 COMPARATIVE ANALYSIS OF BRA CMED, GER G-BA AND FRA HAS ASSESSMENT SCORES FOR ONCOLOGY THERAPIES Boers Trilles, V.
 2019
 19 S p. S21-S22
 artikel
73 PCN24 COST-EFFECTIVENESS OF NIVOLUMAB COMBINED WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FOR PATIENTS WITH BRAF+ MUTATION FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE Lima, J.P.D.S.N.
 2019
 19 S p. S17
 artikel
74 PCN25 COST-EFFECTIVENESS OF NIVOLUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA REGARDLESS OF BRAF MUTATION STATUS FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM Lima, J.P.D.S.N.
 2019
 19 S p. S17-S18
 artikel
75 PCN12 COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO CHEMOTHERAPY AS A TREATMENT FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED MELANOMA IN CHINA Tang, W.
 2019
 19 S p. S15
 artikel
76 PCN16 COST ESTIMATE ANALYSIS OF ABIRATERONE PLUS PREDNISONE (AAP) AND ENZALUTAMIDE (ENZ) IN INSURED METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS IN ARGENTINA: EVIREPRO DATABASE Schmilovich, A.
 2019
 19 S p. S15-S16
 artikel
77 PCN17 COSTO-EFECTIVIDAD DE AFATINIB COMO PRIMERA LÍNEA EN EL TRATAMIENTO DEL CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS AVANZADO CON MUTACIÓN POSITIVA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDÉRMICO EN COLOMBIA Lasalvia, P.
 2019
 19 S p. S16
 artikel
78 PCN20 COSTO EFECTIVIDAD DE LA UTILIZACIÓN DE INHIBIDORES DE PUNTOS DE CONTROL INMUNITARIO (ANTI-PD1/ANTI-CTLA4) Y TERAPIAS DIRIGIDAS (BRAFI/MEKI) EN EL TRATAMIENTO DEL MELANOMA AVANZADO. Pesci, S.
 2019
 19 S p. S16
 artikel
79 PCN6 COSTO-EFECTIVIDAD DEL ESQUEMA DABRAFENIB EN COMBINACIÓN CON TRAMETINIB EN COMPARACIÓN CON OTRAS TERAPIAS DIRIGIDAS, INMUNOTERAPIA Y DACARBAZINA PARA EL TRATAMIENTO DE MELANOMA IRRESECABLE O METASTÁSICO CON MUTACIÓN BRAFV600 EN COLOMBIA Gil Rojas, Y.
 2019
 19 S p. S14
 artikel
80 PCN63 COSTOS ASOCIADOS AL MANEJO DE PACIENTES CON CARCINOMA HEPATOCELULAR EN EL REGIMEN CONTRIBUTIVO Romero Prada, M.
 2019
 19 S p. S24
 artikel
81 PCN7 COSTOS DE LOS EVENTOS ADVERSOS ASOCIADOS CON EL TRATAMIENTO DEL MIELOMA MULTIPLE REFRACTARIO RECIDIVANTE (MMRR) EN ARGENTINA Albaytero, M.N.
 2019
 19 S p. S14
 artikel
82 PCN14 COSTOS INDIRECTOS DEL CANCER DE MAMA EN COLOMBIA: 1990-2016. Vargas-Moranth, R.
 2019
 19 S p. S15
 artikel
83 PCN40 COSTS OF COMPREHENSIVE CARE OF HEPATOCELLULAR CARCINOMA IN A MODEL PUBLIC PROVIDER IN CHILE: IS IT POSSIBLE TO PROMOTE FINANCIAL COVERAGE? Lenz Alcayaga, R.
 2019
 19 S p. S21
 artikel
84 PCN44 DESIGUALDADES EN EL DIAGNÓSTICO DE CÁNCER DE CÉRVIX EN LAS REGIONES DE COLOMBIA Gil Quijano, A.
 2019
 19 S p. S21
 artikel
85 PCN2 EFECTIVIDAD DE LA MAMOGRAFIA EN MUJERES MENORES DE 40 AÑOS: REVISION SISTEMATICA. Pinto, N.
 2019
 19 S p. S13
 artikel
86 PCN1 EFECTIVIDAD Y SEGURIDAD DEL ESQUEMA DABRAFENIB-TRAMETINIB EN EL TRATAMIENTO DEL MELANOMA AVANZADO/METASTÁSICO IRRESECABLE CON MUTACIÓN BRAF V600: REVISIÓN SISTEMÁTICA DE LA LITERATURA Y METANÁLISIS EN RED Garzón-Orjuela, N.
 2019
 19 S p. S13
 artikel
87 PCN21 ESTUDIO DE COSTO EFECTIVIDAD DE NIVOLUMAB PARA EL TRATAMIENTO DE SEGUNDA LINEA DEL CARCINOMA DE CELULAS RENALES METASTASICO DESDE LA PERSPECTIVA DEL SISTEMA DE SALUD PUBLICO CHILENO Balmaceda, C.
 2019
 19 S p. S16-S17
 artikel
88 PCN22 ESTUDIO DE COSTO EFECTIVIDAD DE RIBOCICLIB/LETROZOL PARA EL TRATAMIENTO DEL CANCER DE MAMA METASTASICO CON RECEPTORES DE HORMONA POSITIVO Y HER-2 NEGATIVO DESDE LA PERSPECTIVA DEL SISTEMA DE SALUD PUBLICO CHILENO Balmaceda, C.
 2019
 19 S p. S17
 artikel
89 PCN60 EVALUATION OF EMOTIONAL, SOCIAL AND ACCESS NEEDS OF PATIENTS DIAGNOSED WITH CHRONIC MYELOID LEUKEMIA IN COLOMBIA. Rocha, M.
 2019
 19 S p. S24
 artikel
90 PCN13 EVENTOS ADVERSOS ASOCIADOS A LOS TRATAMIENTOS DEL CARCINOMA UROTERIAL DE VEJIGA Y EL CARCINOMA DE CELULAS RENALES: ESTIMACION DE COSTOS DIRECTOS PARA ARGENTINA Glancszpigel, M.
 2019
 19 S p. S15
 artikel
91 PCN53 EXAMINATION OF PATIENT DELAY AMONG PATIENTS DIAGNOSED WITH PROSTATE CANCER Walter-Molnár, E.
 2019
 19 S p. S23
 artikel
92 PCN36 EXPERIENCIAS EN LA IMPLEMENTACIÓN DE METODOLOGÍAS O CRITERIOS PARA DETERMINAR EL VALOR TERAPÉUTICO DE MEDICAMENTOS ONCOLÓGICOS: UNA REVISIÓN RÁPIDA DE LA LITERATURA Prieto-Pinto, L.
 2019
 19 S p. S20
 artikel
93 PCN37 FDA NEW DRUGS APPROVAL FOR BREAST, COLORECTAL, PROSTATE AND LUNG CANCER AND HORIZON SCANNING OPPORTUNITY Ribeiro, T.
 2019
 19 S p. S20
 artikel
94 PCN8 FINANCIAMIENTO DE MEDICAMENTOS ONCOLOGICOS MEDIANTE EL FONDO INTANGIBLE SOLIDARIO DE SALUD DEL PERU Flores Benites, V.
 2019
 19 S p. S14
 artikel
95 PCN48 HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN ONCOLOGY-RELATED TECHNOLOGIES IN BRAZIL: AN ASSESSMENT CONITEC'S RECOMMENDATIONS FROM 2012-2018 Steffen, R.
 2019
 19 S p. S22
 artikel
96 PCN66 IDENTIFICATION OF PATIENTS UNDERGOING TREATMENT OF LUNG CANCER IN THE BRAZILIAN NATIONAL HEALTH SYSTEM (SUS) Ribeiro, A.
 2019
 19 S p. S25
 artikel
97 PCN26 IMPACTO DE LAS RECAÍDAS EN LOS PACIENTES COLOMBIANOS CON LINFOMA FOLICULAR Moreno, N.A.
 2019
 19 S p. S18
 artikel
98 PCN23 IMPACTO ECONOMICO DE CANCER DE CUELLO UTERINO Y SU TENDENCIA AL 2030 EN EL SISTEMA DE SALUD PUBLICO DEL PERU Gutierrez-Aguado, A.
 2019
 19 S p. S17
 artikel
99 PCN15 IMPACTO ECONOMICO DE LAS COMPLICACIONES OSEAS EN PACIENTES CON CANCER DE MAMA METASTASICO (CAMM) EN MEXICO. Luis Miguel, C.
 2019
 19 S p. S15
 artikel
100 PCN41 IMPACT OF DISEASE RELATED GROUP IN BREAST CANCER TREATMENT IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM Duva, A.
 2019
 19 S p. S21
 artikel
101 PCN42 JUDICIALIZATION OF ACCESS TO MEDICINES IN ONCOLOGY: SYSTEMATIZED REVIEW Mazzuco, C.
 2019
 19 S p. S21
 artikel
102 PCN28 OVARIAN CANCER MORTALITY TREND IN BRAZIL: A LINEAR REGRESSION ANALYSIS BETWEEN 1981 AND 2016 Corrêa, J.S.
 2019
 19 S p. S18
 artikel
103 PCN57 PATIENTS WITH CANCER VIEW PHYSICAL SYMPTOMS AND IMPACT OF SYMPTOMS AS IMPORTANT INFORMATION TO PROVIDE HEALTHCARE PROVIDERS ON A DAILY BASIS Ly, J.
 2019
 19 S p. S23
 artikel
104 PCN47 PEG-ASPARAGINASE E L-ASPARAGINASE NATIVA DE ESCHERICHIA COLI NO TRATAMENTO FARMACOLOGICO DA LEUCEMIA LINFOBLASTICA AGUDA EM CRIANCAS E ADOLESCENTES: UMA REVISAO SISTEMATICA Medawar, C.
 2019
 19 S p. S22
 artikel
105 PCN33 PERTUZUMAB+TRASTUZUMAB TREATMENT ON HER2+ EARLY BREAST CANCER: LONG-TERM REDUCTION OF METASTASIC BREAST CANCER INCIDENCE IN ARGENTINA. Penayo, N.
 2019
 19 S p. S19
 artikel
106 PCN62 PRELIMIANARY ANALYSIS OF TIROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA A FIVE YEARS FOLLOW-UP FROM A REAL WORLD COHORT Cantor, E.
 2019
 19 S p. S24
 artikel
107 PCN32 PROSTATE CANCER MORTALITY TREND IN BRAZIL: A LINEAR REGRESSION ANALYSIS BETWEEN 1981 AND 2016 Alencar Junior, F.D.O.
 2019
 19 S p. S19
 artikel
108 PCN30 REAL-WORLD DATA FOR COSTS RELATED TO CANCER MANAGEMENT IN BRAZIL: AN OVERVIEW OF THE LITERATURE Pereira, A.C.
 2019
 19 S p. S19
 artikel
109 PCN59 SUBJECT TRAINING IS NEEDED FOR KEY TERMINOLOGY IN ONCOLOGY CLINICAL TRIALS Conrad, E.
 2019
 19 S p. S23-S24
 artikel
110 PCN51 SYSTEMATIC REVIEW AND META-ANALYSIS OF 18F-FDG PET-CT FOR INITIAL STAGING OF PATIENTS WITH ESOPHAGEAL CANCER Navega Biz, A.
 2019
 19 S p. S22
 artikel
111 PCN38 SYSTEMATIC REVIEW OF RISK SHARING AGREEMENT IN ONCOLOGY: ADVANCES OR MORE OF THE SAME? Da Veiga, C.
 2019
 19 S p. S20
 artikel
112 PCN29 TENDENCIAS EN LA MORTALIDAD DEL CANCER DE MAMA EN COLOMBIA EN MUJERES MAYORES DE 60 AÑOS Vargas-Moranth, R.
 2019
 19 S p. S18
 artikel
113 PCV4 ANNUAL HEALTH INSURANCE TREATMENT COST OF HYPERTENSIVE RENAL DISEASE IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Endrei, D.
 2019
 19 S p. S26
 artikel
114 PCV7 BUDGET IMPACT OF GLOBAL LONGITUDINAL STRAIN FOR THE EARLY DETECTION OF CARDIOTOXICITY INCORPORATION IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM Rosim, M.P.
 2019
 19 S p. S26
 artikel
115 PCV11 BURDEN OF STERNAL WOUND INFECTIONS FOLLOWING CORONARY ARTERY BYPASS GRAFT PROCEDURE IN SELECT COUNTRIES Mallow, P.
 2019
 19 S p. S27
 artikel
116 PCV8 COST-EFFECTIVENESS ANALYSIS OF A RHEOLYTIC THROMBECTOMY SYSTEM FOR THE TREATMENT OF DEEP VEIN THROMBOSIS IN MEXICO Celis-Luvian, L.
 2019
 19 S p. S26-S27
 artikel
117 PCV6 ECONOMIC EVALUATION OF GLOBAL LONGITUDINAL STRAIN IN THE EARLY DETECTION OF CARDIOTOXICITY IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM Rosim, M.P.
 2019
 19 S p. S26
 artikel
118 PCV13 EFECTIVIDAD DEL CATETER VENOSO DE INSERCION CENTRAL VS EL CATETER VENOSO CENTRAL DE INSERCION PERIFERICA EN EL TRATAMIENTO DE PACIENTES EN LA UNIDAD DE CUIDADOS INTENSIVOS. Arias, M.
 2019
 19 S p. S27
 artikel
119 PCV10 EPIDEMIOLOGICAL STUDY DESIGN TO UNDERSTAND CARDIOVASCULAR RISK FACTORS AND TREATMENT IN GENERAL PRACTICE PATIENTS IN LATIN AMERICA Haider, S.
 2019
 19 S p. S27
 artikel
120 PCV15 GOOD PRACTICES ASSESSMENT FOR CARDIAC SURGERIES: A REAL WORLD ANALYSIS de Paula, E.
 2019
 19 S p. S28
 artikel
121 PCV9 IMPACTO CLINICO Y ECONOMICO DE LAS ENFERMEDADES CARDIOVASCULARES (ECV) EN LA POBLACION ADULTA DENTRO DEL SISTEMA DE SALUD DE MEXICO. Luis Miguel, C.
 2019
 19 S p. S27
 artikel
122 PCV14 IMPACTO DE LA INTERVENCION FARMACEUTICA (IF) EN LA NO ADHERENCIA A TRATAMIENTOS POR OMISION DE RETIRO DE MEDICAMENTOS FINANCIADOS Lalin, M.
 2019
 19 S p. S28
 artikel
123 PCV2 TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) IN ARGENTINA: META-ANALYSIS OF REAL-LIFE DATA Carosella, L.
 2019
 19 S p. S25-S26
 artikel
124 PDB16 AVALIAÇÃO DA EFICÁCIA E SEGURANÇA DO USO DO METIMAZOL EM COMPARAÇÁO A PROPILTIOURACILA PARA HIPERTIREOIDISMO Brito, G.
 2019
 19 S p. S31
 artikel
125 PDB12 BUDGET IMPACT ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION Yagudina, R.
 2019
 19 S p. S30
 artikel
126 PDB11 BUDGET IMPACT ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES Yagudina, R.
 2019
 19 S p. S30
 artikel
127 PDB1 CALIDAD DE VIDA ASOCIADA CON OBESIDAD EN PACIENTES MEXICANOS Escobar Juárez, Y.
 2019
 19 S p. S28
 artikel
128 PDB7 COST COMPARISON OF BOVINE PERICARDIUM (BP) VS. BIOCOMPATIBLE GLYCOLIDE COPOLYMER BUTTRESS IN GASTRIC STAPLE LINE REINFORCEMENT (SLR) Ramirez, M.
 2019
 19 S p. S29
 artikel
129 PDB10 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION Yagudina, R.
 2019
 19 S p. S30
 artikel
130 PDB4 COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES Yagudina, R.
 2019
 19 S p. S29
 artikel
131 PDB6 COSTO DE OBESIDAD Y SU TENDENCIA AL 2030 EN EL SISTEMA DE SALUD PUBLICO DEL PERU Gutierrez-Aguado, A.
 2019
 19 S p. S29
 artikel
132 PDB13 ESTIMATION OF PATIENTS WITH INDICATION OF METABOLIC SURGERY IN THE PUBLIC AND PRIVATE SECTORS IN BRAZIL. Oliveira, F.
 2019
 19 S p. S30-S31
 artikel
133 PDB9 ESTUDIO DE COSTOS DE LA HIPOGLICEMIA EN PACIENTES CON DIABETES MELLITUS TIPO 2 DESDE LA PERSPECTIVA DE SALUD PUBLICA DE CHILE Balmaceda, C.
 2019
 19 S p. S30
 artikel
134 PDB5 IMPACTO ECONOMICO DE HIPERTENSION ARTERIAL Y OBESIDAD EN PERU Lopez-Victorio, S.
 2019
 19 S p. S29
 artikel
135 PDB8 IMPACTO ECONOMICO DE LA DIABETES MELLITUS TIPO II EN EL PERU EN EL ANHO 2017 Licapa, D.
 2019
 19 S p. S29-S30
 artikel
136 PDB18 LA DIABETES Y SUS COMPLICACIONES EN LA ARGENTINA: EL CASO DEL PROGRAMA DE ATENCION INTEGRAL A LOS PACIENTES CON DIABETES MELLITUS EN LAS OBRAS SOCIALES NACIONALES Jankilevich, G.
 2019
 19 S p. S31-S32
 artikel
137 PDB14 LOVASTATIN, ATORVASTATIN AND ROSUVASTATIN CONSUMPTION IN COLOMBIA FROM 2010 TO 2017 Gomez, O.
 2019
 19 S p. S31
 artikel
138 PDB3 PHARMACIST LED INTERVENTION ON HEALTH-RELATED QUALITY OF LIFE OF DIABETIC PATIENTS AND ITS RELATIONSHIP WITH PATIENT DEMOGRAPHICS ON EQ-5D DOMAINS AND VAS SCORE Iqbal, M.Z.
 2019
 19 S p. S28-S29
 artikel
139 PDB2 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) LEVELS IN SELECTED LATIN AMERICAN COUNTRIES — HOW DOES IT MEASURE UP TO MAJOR GLUCOSE MONITORING GUIDELINES? Varughese, B.
 2019
 19 S p. S28
 artikel
140 PDB15 SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR IN TYPE 2 DIABETES: PRESCRIPTION PATTERNS AND TREATMENT OUTCOMES IN ARGENTINA Elgart, J.
 2019
 19 S p. S31
 artikel
141 PDG16 ACESSO A INFORMAÇÕES E SERVIÇOS PRESTADOS PELA SUPERINTENDÊNCIA DE ASSISTÊNCIA FARMACÊUTICA DO ESTADO DE MINAS GERAIS POR MEIO DO APLICATIVO MGAPP Abreu, A.A.P.
 2019
 19 S p. S34
 artikel
142 PDG5 BUDGET IMPACT ANALYSIS OF CLADRIBINE IN HIGH DISEASE ACTIVITY RELAPSE REMITTING MULTIPLE SCLEROSIS IN ARGENTINA Palacios, A.
 2019
 19 S p. S32
 artikel
143 PDG8 COST-EFFECTIVENESS ANALYSIS OF MIDOSTAURIN (MIDO) + INTENSIVE CHEMOTHERAPY (SOC) FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA IN ADULTS WITH FLT3 MUTATION IN COLOMBIA Amezquita, D.
 2019
 19 S p. S33
 artikel
144 PDG10 DRUGS WITH DISCONTINUED PRODUCTION: A DESCRIPTIVE ANALYSIS OF THE BRAZILIAN SCENARIUM Dias, L.
 2019
 19 S p. S33
 artikel
145 PDG9 EVALUACIÓN PARA LA SELECCIÓN DE PRECIO MÁXIMO DE VENTA DE MEDICAMENTOS Romero Prada, M.
 2019
 19 S p. S33
 artikel
146 PDG6 EVALUACION ECONOMICA DE DEXAMETASONA IMPLANTE PARA EL TRATAMIENTO DE PACIENTES CON EDEMA MACULAR DIABETICO Dominguez, V.
 2019
 19 S p. S32
 artikel
147 PDG7 EVALUACION ECONOMICA DE DEXAMETASONA IMPLANTE PARA EL TRATAMIENTO DE PACIENTES CON EDEMA MACULAR DIABETICO CON FALLA A LA TERAPIA ANTI-VEGF (RANIBIZUMAB O AFLIBERCEPT) Esquivel, V.
 2019
 19 S p. S32-S33
 artikel
148 PDG12 EXPERIENCIA INTERNACIONAL EN VALOR TERAPÉUTICO Y PRECIO BASADO EN VALOR. REVISIÓN RÁPIDA DE LA LITERATURA Prieto-Pinto, L.
 2019
 19 S p. S33-S34
 artikel
149 PDG11 IMPLEMENTATION OF INDICATORS IN THE PROCESS OF ACQUISITION OF MEDICINES IN THE HOSPITAL UNITS OF THE STATE SECRETARIAT OF HEALTH OF SANTA CATARINA: THE USE OF THE ECONOMIC RATIO INDEX Rodrigues, C.R.F.
 2019
 19 S p. S33
 artikel
150 PDG1 POLIMIXINA B: EXISTEM FATORES DE RISCO ASSOCIADOS À NEFROTOXICIDADE EM PACIENTES QUE UTILIZARAM ESTE MEDICAMENTO? Tonin, F.S.
 2019
 19 S p. S32
 artikel
151 PDG15 SOLICITAÇÃO DE MEDICAMENTOS DO COMPONENTE ESPECIALIZADO NO ESTADO DE MINAS GERAIS: ESTRATÉGIA PARA REDUÇÃO DO TEMPO DE TRAMITAÇÃO E OTIMIZAÇÃO DESSE PROCESSO Abreu, A.A.P.
 2019
 19 S p. S34
 artikel
152 PGI5 BURDEN OF LIVER DISEASE, COLOMBIA 2009-2016 Bejarano, D.
 2019
 19 S p. S35
 artikel
153 PGI6 CARGA DE ENFERMEDAD DIARREICA AGUDA ASOCIADA A MALA CALIDAD DEL AGUA, FALTA DE SANEAMIENTO E HIGIENE DE MANOS EN COLOMBIA, 2016 Valencia, S.
 2019
 19 S p. S35
 artikel
154 PGI1 EFFECTS OF FECAL MICROBIOTA TRANSPLANTATION IN INFLAMMATORY BOWEL DISEASE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS Borba, H.H.
 2019
 19 S p. S34
 artikel
155 PGI3 IMPACT OF DOSE ESCALATION ON TREATMENT COST OF IMMUNOBIOLOGICAL THERAPIES FOR CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE PAYER PERSPECTIVE Fioratti, C.
 2019
 19 S p. S34-S35
 artikel
156 PGI9 PRIOR DIAGNOSIS OF GASTROINTESTINAL DISORDER DOES NOT INCREASE KNOWLEDGE OF GASTROINTESTINAL TERMINOLOGY OR ACCURACY OF SYMPTOM RATING Peechatka, A.
 2019
 19 S p. S35
 artikel
157 PIH6 APPROACH TO THE IMPACT OF COVERAGE IN LONG-TERM CONTRACEPTION IN THE ECONOMIC BURDEN OF UNPLANNED PREGNANCY FROM THE PERSPECTIVE OF ISAPRES IN CHILE Morris, C.
 2019
 19 S p. S36
 artikel
158 PIH3 BUDGET IMPACT ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION Yagudina, R.
 2019
 19 S p. S36
 artikel
159 PIH14 BURDEN OF PNEUMOCOCCAL DISEASE HOSPITALIZATIONS IN OLDER ADULTS 60Y+ IN FIVE CAPITALS IN BRAZIL Chabrol Haas, L.
 2019
 19 S p. S38
 artikel
160 PIH13 CLINICAL BURDEN AND COSTS ASSOCIATED WITH PNEUMOCOCCAL DISEASE HOSPITALIZATIONS IN OLDER ADULTS IN CURITIBA, BRAZIL Chabrol Haas, L.
 2019
 19 S p. S37-S38
 artikel
161 PIH19 CONTRASTE DE MODELOS DE PROBABILIDAD DICOTOMICOS PARA LA ESTIMACION DE PARTOS Y CESAREAS EN UNA ENTIDAD PROMOTORA DE SALUD COLOMBIANA Romero Prada, M.
 2019
 19 S p. S39
 artikel
162 PIH2 COST-EFFECTIVENESS ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION Yagudina, R.
 2019
 19 S p. S36
 artikel
163 PIH1 COSTOS DIRECTOS FARMACÉUTICOS EN PACIENTES ANCIANOS CON POLIFARMACIA EXTREMA MAYOR DE 20 MEDICAMENTOS EN COLOMBIA Machado-Duque, M.
 2019
 19 S p. S35
 artikel
164 PIH15 CURRENT PANORAMA OF THE SURGICAL TREATMENT OF ENDOMETRIOSIS BY THE BRAZILIAN PUBLIC SYSTEM Gibran, L.
 2019
 19 S p. S38
 artikel
165 PIH11 ESTIMACION DE LA VARIACION DE COSTOS PRIVADOS E INSTITUCIONALES DE TRATAMIENTO DE LA DISMENORREA PRIMARIA EN MUJERES MEXICANAS. Guzman Vazquez, S.
 2019
 19 S p. S37
 artikel
166 PIH18 EVALUATION OF INFORMATION SHARING IN CONNECTION WITH SCHOOL HEALTH ATTENDANCE AND ITS EFFECTS ON THE ATTENDANCE OF HEALTH SERVICE Karácsony, I.
 2019
 19 S p. S38
 artikel
167 PIH9 IMPACTO ECONOMICO DE ANEMIA Y SU TENDENCIA AL 2030 EN EL SISTEMA DE SALUD PUBLICO DEL PERU Gutierrez-Aguado, A.
 2019
 19 S p. S36-S37
 artikel
168 PIH8 MODEL TO APPROACH TO THE ECONOMIC BURDEN OF UNPLANNED PREGNANCY IN CHILE: THE IMPACT OF THE FAILURE OF COMPLIANCE OF THE CONTRACEPTIVE METHODS. Escobar, D.
 2019
 19 S p. S36
 artikel
169 PIH10 NATIONWIDE, REAL-WORLD HEALTH INSURANCE TREATMENT COST OF INFERTILITY IN HUNGARY: A COST OF ILLNESS STUDY Boncz, I.
 2019
 19 S p. S37
 artikel
170 PIH24 NUEVAMENTE: CALIDAD DE VIDA EN PERSONAS MAYORES DE UN SEGURO PRIVADO DE SALUD EN COLOMBIA Posada, K.
 2019
 19 S p. S39
 artikel
171 PIH16 PATRONES DE USO DE ANTICONCEPTIVOS HORMONALES EN UNA POBLACIÓN DE COLOMBIA. Machado-Duque, M.
 2019
 19 S p. S38
 artikel
172 PIH23 SISTEMATIZACION DE EXPERIENCIAS EN EL DESARROLLO DE UNA ESTRATEGIA NO CONVENCIONAL PARA EDUCAR EN SALUD A GESTANTES DEL PROGRAMA SER MADRE-HIJO DE MUTUAL SER EPS. Moyano, L.
 2019
 19 S p. S39
 artikel
173 PIH12 THE ECONOMIC IMPACT OF ENDOMETRIOSIS IN BRAZIL DUE TO PRODUCTIVITY LOSS Souza, L.
 2019
 19 S p. S37
 artikel
174 PIN4 A BUDGET IMPACTO ANALYSIS OF TENOFOVIR ALAFENAMIDE/EMTRICITABINE (DESCOVY®) FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PATIENTS AGED 12 YEARS AND OLDER, IN MEXICO Leal-González, M.
 2019
 19 S p. S40
 artikel
175 PIN8 ANALISE ECONOMICA DE CUSTOS DE TRATAMENTO DE INFECCOES POR MICROORGANISMOS GRAM-POSITIVOS RESISTENTES: STAPHYLOCOCCUS AUREUS RESISTENTE A METICILINA (MRSA) E ENTEROCOCCUS SPP RESISTENTES A VANCOMICINA (VRE) Moura, C.C.
 2019
 19 S p. S41
 artikel
176 PIN13 BUDGET IMPACT ANALISIS ( BIA) OF THE IMPLEMENTATION OF HIGH-RISK HPV GENOTYPING IN PATIENTS OF THE SOCIAL SECURITY OF ECUADOR (IESS) FOR PREVENTION OF CERVICAL CANCER Cecilia, C.
 2019
 19 S p. S42
 artikel
177 PIN18 BURDEN OF ILLNESS OF HERPES ZOSTER IN COLOMBIA: AN OBSERVATIONAL STUDY Rampakakis, E.
 2019
 19 S p. S43
 artikel
178 PIN25 CALIDAD DE REVISIONES SISTEMATICAS CON EVALUACIONES DE COSTO-EFECTIVIDAD DE LA VACUNA CONTRA ROTAVIRUS DE PAISES LATINOAMERICANOS Castañeda Guerrero, C.
 2019
 19 S p. S44
 artikel
179 PIN1 COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR HIGH RISK PATIENTS IN THE PERSPECTIVE OF BRAZILIAN NIP Alexandre, R.F.
 2019
 19 S p. S40
 artikel
180 PIN11 COST-EFFECTIVENESS OF INTERFERON-GAMMA RELEASE ASSAY COMPARED TO TUBERCULIN SKIN TEST FOR DETECTION OF LATENT TUBERCULOSIS IN PATIENTS WITH RENAL FAILURE UNDERGOING HEMODIALYSIS Rosim, M.P.
 2019
 19 S p. S42
 artikel
181 PIN12 COST-EFFECTIVENESS OF INTERFERON-GAMMA RELEASE ASSAY COMPARED TO TUBERCULIN SKIN TEST FOR DETECTION OF LATENT TUBERCULOSIS IN RHEUMATOID ARTHRITIS PATIENTS USING IMMUNOBIOLOGICAL TREATMENTS Rosim, M.P.
 2019
 19 S p. S42
 artikel
182 PIN3 COSTS AND CONSEQUENCES OF CEFTAROLINE FOSAMIL FOR THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM Alexandre, R.F.
 2019
 19 S p. S40
 artikel
183 PIN28 COSTS OF PERTUSSIS IN BRAZIL: A NINE-YEAR EVALUATION de Jesus Lopes de Abreu, A.
 2019
 19 S p. S45
 artikel
184 PIN5 CUSTO COM ANTIMICROBIANOS NO TRATAMENTO DE INFECCAO MULTIRRESISTENTE AOS CARBAPENEMICOS: VISAO DE UMA OPERADORA DE SAUDE Mariano, A.C.M.
 2019
 19 S p. S40-S41
 artikel
185 PIN7 ECONOMIC EVALUATION OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (GENVOYA®) AS A COMPLETE TREATMENT REGIMEN FOR HIV-1 INFECTION IN ADULTS WHO ARE ANTIRETROVIRAL THERAPY-NAÏVE IN MEXICO Paladio Hernández, J.Á.
 2019
 19 S p. S41
 artikel
186 PIN16 ESTIMATED ANNUAL IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IMMUNIZATION PROGRAM IN COLOMBIA (2011-2018) Caceres, D.
 2019
 19 S p. S43
 artikel
187 PIN23 EVALUACIÓN DE LAS PROPIEDADES PSICOMÉTRICAS DEL EQ-5D-5L EN PACIENTES CON VIH/SIDA EN COLOMBIA Muñoz-Galindo, I.M.
 2019
 19 S p. S44
 artikel
188 PIN14 INCREMENTAL PUBLIC HEALTH AND ECONOMIC IMPACT LINKED TO HIGHER VACCINE COVERAGE RATE IN A GENDER-NEUTRAL QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM IN BRAZIL Batista, P.M.
 2019
 19 S p. S43
 artikel
189 PIN22 LOS COSTOS DE LA NEUMONIA ADQUIRIDA EN LA COMUNIDAD Y LA LACTANCIA MATERNA COMO FACTOR DE PROTECCION EN MENORES DE 5 ANHOS EN HOSPITAL PUBLICO DEL PERU Montalvo-Orellana, J.
 2019
 19 S p. S44
 artikel
190 PIN6 O IMPACTO ECONOMICO NA AVALIACAO DO INFECTOLOGISTA NO PROGRAMA DE GESTAO CLINICA DO USO DE ANTIMICROBIANOS EM HOSPITAL PRIVADO DE FORTALEZA- CE, BRASIL Romero, J.F.
 2019
 19 S p. S41
 artikel
191 PIN20 OVERVIEW OF MORTALITY DUE TO ANTIMICROBIAL RESISTANT INFECTIONS Salvador, B.C.
 2019
 19 S p. S43-S44
 artikel
192 PIN26 PRINCIPALES ESQUEMAS ANTIRRETROVIRALES USADOS EN LAS PERSONAS QUE VIVEN CON EL VIH EN COLOMBIA. 2018 Castillo, J.C.
 2019
 19 S p. S45
 artikel
193 PIN21 PROFILING PURCHASE VOLUMES AND EXPENDITURES WITH DIRECT-ACTING ANTIRETROVIRALS FOR HEPATITIS C BY THE BRAZILIAN MINISTRY OF HEALTH, 2015-2018 Caetano, R.
 2019
 19 S p. S44
 artikel
194 PIN9 PUBLIC HEALTH AND ECONOMIC IMPACT OF A GENDER-NEUTRAL QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM IN COLOMBIA Carrasquilla, M.
 2019
 19 S p. S41-S42
 artikel
195 PIN10 PUBLIC HEALTH AND ECONOMIC IMPACT OF A HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM FOR FEMALES AGED 9 YEARS IN EL SALVADOR Rendon, A.M.
 2019
 19 S p. S42
 artikel
196 PIN15 PUBLIC HEALTH IMPACT OF DENGUE VACCINATION WITH SCREENING IN BRAZIL Boiron, L.
 2019
 19 S p. S43
 artikel
197 PIN2 SISTEMA ELETRONICO INTEGRADO NO GERENCIAMENTO DO PROGRAMA STEWARDSHIP NUMA OPERADORA DE PLANOS DE SAUDE Neto, V.D.S.L.
 2019
 19 S p. S40
 artikel
198 PIN27 USO DE LA REGRESIÓN BETA EN EL ANALISIS DE ASOCIACIÓN ENTRE LOS ÍNDICES EQ-5D-5L, EQ-EVA Y POTENCIALES COVARIABLES EN PACIENTES CON VIH/SIDA EN COLOMBIA Muñoz-Galindo, I.M.
 2019
 19 S p. S45
 artikel
199 PIT6 SELF-INFLICTED LESIONS IN BRAZIL: A DESCRIPTIVE ANALYSIS BETWEEN 2009 AND 2016 Felix, C.G.
 2019
 19 S p. S45-S46
 artikel
200 PIT4 SILICONE TAPES FOR PATIENTS WITH FRAGILE SKIN: A SYSTEMATIC REVIEW Santos, A.
 2019
 19 S p. S45
 artikel
201 PIT7 THE PROFILE OF FIREARMS INJURIES IN BRAZIL BETWEEN 2009 AND 2016 de Lima, A.A.
 2019
 19 S p. S46
 artikel
202 PMD3 ANALISIS DE IMPACTO PRESUPUESTARIO SOBRE LA INCORPORACION DEL COCIENTE SFLT-1/PLGF PARA PREDECIR EL RIESGO DE PREECLAMPSIA EN EL SANATORIO FINOCHIETTO DE ARGENTINA Garay, U.
 2019
 19 S p. S46
 artikel
203 PMD4 ANALISIS DE IMPACTO PRESUPUESTARIO SOBRE LA INCORPORACION DEL COCIENTE SFLT-1/PLGF PARA PREDECIR EL RIESGO DE PREECLAMPSIA EN EL SISTEMA DE SALUD PUBLICO DE MENDOZA, ARGENTINA Garay, U.
 2019
 19 S p. S47
 artikel
204 PMD2 ANALISIS DE IMPACTO PRESUPUESTARIO Y SANITARIO POR LA INCORPORACION DE UN DISPOSITIVO PORTATIL PARA EL CONTROL DE LOS PACIENTES ANTICOAGULADOS EN LA POBLACION DEL INSTITUTO NACIONAL DE SERVICIOS SOCIALES PARA JUBILADOS Y PENSIONADOS (PAMI) DE ARGENTINA Garay, U.
 2019
 19 S p. S46
 artikel
205 PMD5 ANALISIS DEL IMPACTO SANITARIO Y PRESUPUESTARIO POR LA INCORPORACION DEL TEST DE HPV CON GENOTIPIFICACION PARA EL TAMIZAJE PRIMARIO DE CANCER CERVICAL EN UNA POBLACION CERRADA DE UN HOSPITAL UNIVERSITARIO DE LA CIUDAD DE BUENOS AIRES Garay, U.
 2019
 19 S p. S47
 artikel
206 PMD13 BUNDLE AND RISK SHARING FOR BARIATRIC SURGERY UNDER THE VALUE-BASED CARE (VBC) MODEL: MODEL EFFECTIVENESS AND SUSTAINABILITY AT HOSPITAL ALEMAO OSWALDO CRUZ (HAOC) BASED IN CLINICAL AND ECONOMICAL RESULTS Cohen, R.
 2019
 19 S p. S48-S49
 artikel
207 PMD6 CENTRIFUGAL VERSUS MEMBRANE THERAPEUTIC PLASMA EXCHANGE: A CHILEAN, MULTI-CENTER, COST-COMPARISON STUDY Comasòlivas, N.
 2019
 19 S p. S47
 artikel
208 PMD9 COST-EFFECTIVENESS ANALYSIS OF THREE-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY VERSUS TWO-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAM FOR THE EVALUATION OF PATIENTS WITH MITRAL REGURGITATION WITH INDICATION OF SURGICAL TREATMENT dos Santos, W.M.
 2019
 19 S p. S47-S48
 artikel
209 PMD8 COST-EFFECTIVENESS OF THERMOABLATION VERSUS SURGERY FOR TREATMENT OF LIVER METASTASIS dos Santos, W.M.
 2019
 19 S p. S47
 artikel
210 PMD10 ESTUDIO MULTICÉNTRICO DE COSTOS DEL RECAMBIO PLASMÁTICO TERAPÉUTICO (RPT) CON LOS SISTEMAS DE FILTRACIÓN TRANSMEMBRANA Y DE CENTRIFUGACIÓN EN COLOMBIA Comasòlivas, N.
 2019
 19 S p. S48
 artikel
211 PMD12 HOW MUCH CAN COLOMBIAN HOSPITALS EARN FOR EACH THERAPEUTIC PLASMA EXCHANGE (TPE) PROCEDURE? A MULTI-CENTER, COST COMPARISON STUDY BETWEEN CENTRIFUGAL AND MEMBRANE SYSTEMS Comasòlivas, N.
 2019
 19 S p. S48
 artikel
212 PMD1 PATIENT OUTCOMES IN CENTRIFUGE AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE (TPE): LITERATURE REVIEW WITH A FOCUS ON THE CHILEAN & COLOMBIAN MARKETS Comasòlivas, N.
 2019
 19 S p. S46
 artikel
213 PMD11 REMOTE MONITORING COMPARED TO CONVENTIONAL FOLLOW-UP FOR PATIENTS WITH HEART FAILURE USING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR: A COST-EFFECTIVENESS ANALYSIS Lucchetta, R.C.
 2019
 19 S p. S48
 artikel
214 PMH11 BURDEN OF MENTAL ILLNESS IN THE PRESENCE OF CHRONIC DISEASES IN THE BRAZILIAN PRIVATE HEALTH de Paula, E.
 2019
 19 S p. S51
 artikel
215 PMH7 COST-EFFECTIVENESS AND INCORPORATION PRICE OF ARIPIPRAZOLE FOR SCHIZOPHRENIA IN BRAZIL: A SUBSTITUTE TECHNOLOGY APPROACH Santos, A.
 2019
 19 S p. S50
 artikel
216 PMH6 COST-EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS FOR FIRST- AND SECOND-LINE TREATMENT OF SCHIZOPHRENIA IN BRAZIL Santos, A.
 2019
 19 S p. S49-S50
 artikel
217 PMH1 COST-OF-ILLNESS STUDIES FOR DEPRESSION AND BIPOLAR DISORDER IN LATIN AMERICA: A SYSTEMATIC REVIEW Parra Padilla, D.
 2019
 19 S p. S49
 artikel
218 PMH3 ESKETAMINE SELF-PAY MODEL FOR TREATMENT RESISTANT DEPRESSION IN MEXICO Zhang, S.
 2019
 19 S p. S49
 artikel
219 PMH8 EXPERIENCES AND HEALTH NEEDS OF ASYLUM SEEKERS AND REFUGEES OF LATIN AMERICAN ORIGIN IN CHILE Carreño, A.
 2019
 19 S p. S50
 artikel
220 PMH9 IMPACTO DE FACTORES SOCIOLOGICOS EN LA CALIDAD DE VIDA DE ADULTOS MAYORES INSTITUCIONALIZADOS CON DEPRESION: REVISION SISTEMATICA Bravo, N.
 2019
 19 S p. S50
 artikel
221 PMH4 STROKE IN BRAZIL: COST OF ILLNESS ON THE LENGTH OF SATY IN HOSPITAL Brito, G.
 2019
 19 S p. S49
 artikel
222 PMH2 THE ENVIRONMENT DISASTER OF BRAZILIAN MINING OF MARIANA IN THE HEALTH ECONOMIC CONTEXT: PSYCHOLOGICAL TRAGEDY COST Lins, L.
 2019
 19 S p. S49
 artikel
223 PMH10 TREATMENT-RESISTANT DEPRESSION IN LATIN AMERICA: PRELIMINARY RESULTS FROM THE TRAL STUDY Teng, C.T.
 2019
 19 S p. S50-S51
 artikel
224 PMS13 A ROUTE FOR THE CORRECT DIAGNOSIS OF RHEUMATOID ARTHRITIS - AN OPPORTUNITY TO AVOID MISDIAGNOSIS AND COSTS ASSOCIATED Santos-Moreno, P.
 2019
 19 S p. S54
 artikel
225 PMS7 A STANDARD COSTING FOR MODERATE-SEVERE RHEUMATOID ARTHRITIS FROM THE COLOMBIAN HEALTH SYSTEM PERSPECTIVE Alvis-Zakzuk, N.J.
 2019
 19 S p. S52
 artikel
226 PMS12 BENEFICIOS CLINICOS Y ECONOMICOS EN LA IMPLEMENTACION DE UNIDADES DE COORDINACION DE FRACTURAS (FLS) EN MEXICO Luis Miguel, C.
 2019
 19 S p. S53-S54
 artikel
227 PMS16 COMPARING QUALITY OF LIFE, SYMPTOMS, AND TREATMENT PATTERNS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS: FINDINGS FROM A GLOBAL SURVEY Hunter, T.
 2019
 19 S p. S54
 artikel
228 PMS8 CONVENTIONAL VERSUS BIOLOGICAL TREATMENT FOR ANKYLOSING SPONDYLITIS. RESULTS FROM A REAL-LIFE SETTING Santos-Moreno, P.
 2019
 19 S p. S52-S53
 artikel
229 PMS18 COST-ANALYSIS OF TREATMENT FOR MODERATE AND SEVERE RHEUMATOID ARTHRITIS IN A SPECIALIZED RHEUMATOLOGY CENTER Santos-Moreno, P.
 2019
 19 S p. S54-S55
 artikel
230 PMS20 DADOS DE MUNDO REAL DO USO DE IMUNOBIOLOGICOS DE PACIENTES COM ARTRITE REUMATOIDE Vieira, J.B.
 2019
 19 S p. S55
 artikel
231 PMS11 EPIDEMIOLOGY, USE OF RESOURCES AND COST OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ARGENTINA: AN EXTENSIVE REVIEW WITH EXPERT ELICITATION Alfie, V.
 2019
 19 S p. S53
 artikel
232 PMS9 EVALUACIÓN DE LA INCLUSIÓN DE DENOSUMAB EN EL PLAN DE BENEFICIOS DE SALUD EN COLOMBIA PARA EL TRATAMIENTO DE LA OSTEOPOROSIS: ANÁLISIS DE IMPACTO PRESUPUESTAL Forero, J.
 2019
 19 S p. S53
 artikel
233 PMS19 MANAGEMENT AND COSTS OF THERAPY FOR OSTEOARTHRITIS Santos-Moreno, P.
 2019
 19 S p. S55
 artikel
234 PMS4 MEDICATION PATTERNS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - CHARACTERISTICS AND COSTS OF THERAPY Santos-Moreno, P.
 2019
 19 S p. S51-S52
 artikel
235 PMS10 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF JUVENILE AND ADOLESCENT IDIOPATHIC SCOLIOSIS IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Boncz, I.
 2019
 19 S p. S53
 artikel
236 PMS17 PATIENT PREFERENCES FOR BIOLOGIC AND BIOSIMILAR OSTEOPOROSIS TREATMENTS IN COLOMBIA: A DISCRETE-CHOICE EXPERIMENT Leonardi Reyes, F.
 2019
 19 S p. S54
 artikel
237 PMS3 PSYCHOLOGY CONSULTATION FOR PATIENTS WITH RHEUMATOID ARTHRITIS - A LOW-COST INTERVENTION WITH GREAT BENEFITS Santos-Moreno, P.
 2019
 19 S p. S51
 artikel
238 PMS6 STANDARD COSTING OF DIRECT COSTS FOR PATIENTS WITH OSTEOARTHROSIS IN THE FIRST YEAR AFTER THE DISEASE WAS DIAGNOSED Santos-Moreno, P.
 2019
 19 S p. S52
 artikel
239 PMS2 SUCCESSFUL IMPLEMENTATION OF A COMPREHENSIVE CARE PROGRAM IN RHEUMATOID ARTHRITIS WITH SIGNIFICANT COST-SAVINGS FOR THE HEALTH SYSTEM Santos-Moreno, P.
 2019
 19 S p. S51
 artikel
240 PMS1 SUSTAINED REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS: EVIDENCE FROM A COHORT FOLLOWED-UP AT A CENTER OF EXCELLENCE IN COLOMBIA Alvis-Estrada, J.P.
 2019
 19 S p. S51
 artikel
241 PMS5 USE OF AN ALGORITHM WITHIN A MULTIDISCIPLINARY CONSULTATION FOR THE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS CANDIDATES FOR BIOLOGICAL THERAPY - A STRATEGY FOR OPTIMIZING COSTS Santos-Moreno, P.
 2019
 19 S p. S52
 artikel
242 PMU15 A MOBILE PHONE APP HEALTH CARE PROGRAM IN BRAZIL: SELF-REPORTS TO ASSESS DISEASE PREVALENCE Picoli, R.
 2019
 19 S p. S58
 artikel
243 PMU13 A MULTI-CRITERIA APPROACH TO THE STUDY OF CHRONIC NON-COMMUNICABLE DISEASES IN BRAZIL Sallum, F.S.V.
 2019
 19 S p. S58
 artikel
244 PMU6 ANALISIS DE COSTOS EN CUIDADO INTENSIVO Y CUIDADOS INTERMEDIOS DE UNA ASEGURADORA EN SALUD EN COLOMBIA Fernandez Mercado, J.C.
 2019
 19 S p. S56
 artikel
245 PMU12 A NON-COMMUNICABLE DISEASES MULTI-CRITERIA ANALYSIS IN LATIN AMERICA Sallum, F.S.V.
 2019
 19 S p. S57-S58
 artikel
246 PMU11 COMPARATIVE ASSESSMENT OF HTA OUTCOMES IN BRAZIL, CANADA AND THE UNITED KINGDOM Boers Trilles, V.
 2019
 19 S p. S57
 artikel
247 PMU3 COSTOS DIRECTOS DE LA ATENCIÓN EN PACIENTES SUSCEPTIBLES DE CUIDADOS PALIATIVOS, EL CASO DE UNA ASEGURADORA EN SALUD EN COLOMBIA Hoyos, F.
 2019
 19 S p. S56
 artikel
248 PMU2 COSTOS DIRECTOS MÉDICOS EN COLOMBIA DESCRITOS EN EL ESTUDIO COMPASS: EVENTOS CARDIACOS AGUDOS MAYORES (MACE) Y EVENTOS ISQUEMICOS SEVEROS EN EXTREMIDADES (MALE) Chamorro, C.
 2019
 19 S p. S55
 artikel
249 PMU8 DIFERENCIAS EN LA MORTALIDAD SEGUN LUGAR DE OCURRENCIA Y REGIMEN DE SALUD EN EL CARIBE COLOMBIANO, 2016 Vargas-Moranth, R.
 2019
 19 S p. S56-S57
 artikel
250 PMU9 ESTABLISHING CHILE RICARTE SOTO LAW REIMBURSEMENT CAP IN THE FACE OF GENERIC COMPETITION Boers Trilles, V.
 2019
 19 S p. S57
 artikel
251 PMU4 ESTIMATING THE ECONOMIC BURDEN OF DISEASE FROM WATER, SANITATION AND HYGIENE IN COLOMBIA Alvis-Zakzuk, N.J.
 2019
 19 S p. S56
 artikel
252 PMU7 POPULATION HEALTH IMPACT MODEL Djurdjevic, S.
 2019
 19 S p. S56
 artikel
253 PMU1 POTENTIAL PRODUCTIVITY YEARS OF LIFE LOST RELATED TO DEATHS CAUSED BY RESIDENTIAL RADON AND BONE LEAD IN COLOMBIA, 2016 Alvis-Zakzuk, N.J.
 2019
 19 S p. S55
 artikel
254 PMU10 RESULTADOS DE IMPLEMENTACION DE PROGRAMA DE CUIDADOS PALIATIVOS EN UNA ASEGURADORA EN SALUD EN COLOMBIA Fernandez Mercado, J.C.
 2019
 19 S p. S57
 artikel
255 PMU14 USO DEL EQ-5D EN MEXICO Falcón Gerónimo, J.J.
 2019
 19 S p. S58
 artikel
256 PND4 ANALISIS DE MINIMIZACION DE COSTOS DE TOPIRAMATO DE LIBERACION PROLONGADA PARA LA PREVENCION DE MIGRAÑA EN ADULTOS Y ADOLESCENTES A PARTIR DE LOS 12 AÑOS Esquivel, V.
 2019
 19 S p. S59
 artikel
257 PND8 ANALISIS DE MINIMIZACION DE COSTOS DE TOXINA ONABOTULINICA A 100 U EN PACIENTES CON BLEFAROESPASMO Y TORTICOLIS ESPASMODICA Soto Molina, H.
 2019
 19 S p. S60
 artikel
258 PND9 BUDGET IMPACT ANALYSIS OF CLADRIBINE COMPARED TO THE CURRENT COVERAGE SCHEME IN CHILE TO TREAT PATIENTS WITH HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS Balmaceda, C.
 2019
 19 S p. S60
 artikel
259 PND15 CHARACTERIZATION OF THE ARGENTINE POPULATION WITH AT LEAST 4 MONTHLY MIGRAINE DAYS: RESULTS FROM MIGRAINE VOICE SURVEY Luque, P.S.
 2019
 19 S p. S62
 artikel
260 PND10 COMPARATIVE EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FURMURATE VERSUS OTHER DISEASE-MODIFYING THERAPIES IN PATIENTS WITH MULTIPLE SCLEROSIS: A DIRECT META-ANALYSIS OF REAL-WORLD EVIDENCE Lewin, J.B.
 2019
 19 S p. S60-S61
 artikel
261 PND1 COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE IN HIGH DISEASE ACTIVITY RELAPSE REMITTING MULTIPLE SCLEROSIS IN ARGENTINA Espinola, N.
 2019
 19 S p. S58
 artikel
262 PND7 COST-EFFECTIVENESS OF CLADRIBINE COMPARED TO NATALIZUMAB, OCRELIZUMAB AND ALEMTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS IN CHILE Espinoza, M.A.
 2019
 19 S p. S60
 artikel
263 PND5 COST-EFFECTIVENESS OF MECHANICAL THROMBECTOMY USING SOLITAIRE STENT RETRIEVER IN COMBINATION WITH INTRAVENOUS TISSUE PLASMINOGEN ACTIVATOR (IV-TPA) VERSUS IV-TPA ALONE FOR THE TREATMENT OF ACUTE ISCHAEMIC STROKE DUE TO LARGE VESSEL OCCLUSION IN COLOMBIA Pabon, B.
 2019
 19 S p. S59
 artikel
264 PND3 COST-UTILITY ANALYSIS OF NATALIZUMAB AS FIRST LINE THERAPY FOR HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS FROM A BRAZILIAN PRIVATE PAYER PERSPECTIVE Rosim, R.
 2019
 19 S p. S59
 artikel
265 PND11 ECONOMIC IMPACT OF INITIATING DIMETHYL FUMARATE VERSUS OTHER DISEASE MODYFING THERAPIES IN PUBLICLY INSURED BRAZILIAN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS Rock, M.
 2019
 19 S p. S61
 artikel
266 PND14 OUT-OF-POCKET EXPENDITURE IN MIGRAINE PATIENTS WITH AND WITHOUT COMORBIDITIES IN CHILE: A HEALTHCARE SYSTEM PERSPECTIVE Paredes, D.
 2019
 19 S p. S61
 artikel
267 PND16 PREFERENCES OF PATIENTS FOR FEATURES OF INJECTABLE, ORAL, AND INFUSED DISEASE-MODIFYING TREATMENTS FOR RELAPSE-REMITTING MULTIPLE SCLEROSIS Poulos, C.
 2019
 19 S p. S62
 artikel
268 PND19 RETROSPECTIVE ANALYSIS OF MULTIPLE SCLEROSIS TREATMENT PROFILE AND PATTERNS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM Murta Amaral, L.
 2019
 19 S p. S62-S63
 artikel
269 PND13 SYSTEMATIC REVIEW OF THE COST OF ILLNESS OF MULTIPLE SCLEROSIS González, L.M.
 2019
 19 S p. S61
 artikel
270 PND17 THE BURDEN OF MIGRAINE IN LATIN AMERICA Papadimitropoulos, M.
 2019
 19 S p. S62
 artikel
271 PND6 THE DIRECT COSTS OF MULTIPLE SCLEROSIS IN A GROUP OF COLOMBIAN PATIENTS Ortiz Salas, P.A.
 2019
 19 S p. S59-S60
 artikel
272 PND18 THE RESTORE REGISTRY: A RESOURCE FOR MEASURING AND IMPROVING SPINAL MUSCULAR ATROPHY OUTCOMES Servais, L.
 2019
 19 S p. S62
 artikel
273 PND2 TREATMENTS FOR HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS: COST-EFFECTIVENESS ANALYSIS IN COLOMBIA Lasalvia, P.
 2019
 19 S p. S59
 artikel
274 PND12 WORK PRODUCTIVITY AND DAILY ACTIVITIES IMPAIRMENT (WPAI) IN CHILEAN PATIENTS WITH MIGRAINE: PERSPECTIVES ON INDIRECT-COSTS DRIVERS Lenz Alcayaga, R.
 2019
 19 S p. S61
 artikel
275 PNS50 ANALISIS DE IMPACTO DE LA IMPLEMENTACION DE UNA RED INTEGRADA MEDIANTE LA MEDIDA DE CALIDAD DE VIDA RELACIONADA CON LA SALUD EN POBLACION COLOMBIANA Romero Prada, M.
 2019
 19 S p. S72
 artikel
276 PNS16 ANALYSIS OF THE DEMAND AND CONCESSIONS OF THE CONTINUED CASH BENEFIT FOR PERSONS WITH DISABILITIES UNDER 16 YEARS Campos, M.D.D.
 2019
 19 S p. S65
 artikel
277 PNS19 AN ANALYSIS OF CONTINUED CASH BENEFIT: PERSONS WITH DISABILITIES OVER 16 YEARS OLD Kohatsu, G.L.
 2019
 19 S p. S66
 artikel
278 PNS47 ANÁLISIS PARA LA IMPLEMENTACIÓN DE NUEVOS MODELOS DE ACCESO PARA EL SISTEMA NACIONAL DE SALUD DEL ECUADOR Gavilanes, C.
 2019
 19 S p. S71
 artikel
279 PNS45 APPLYING A RAPID REVIEW METHODOLOGY TO INFORM THE UPDATE OF ARGENTINA'S HEALTH BENEFIT PACKAGE Alfie, V.
 2019
 19 S p. S71
 artikel
280 PNS42 A SURVEY OF PRACTICING PHYSICIANS ON VALUE-BASED HEALTH CARE IN A PRIVATE HEALTH SYSTEM IN BRAZIL Makdisse, M.
 2019
 19 S p. S70
 artikel
281 PNS46 ATENCION VIRTUAL EN SALUD: DE LA ESTRATEGIA A LA TACTICA Orrego, S.
 2019
 19 S p. S71
 artikel
282 PNS54 AUDITORIA SOCIAL COMO FERRAMENTA DE ANALISE DA QUALIDADE DO ATENDIMENTO NA SAUDE Viana, A.
 2019
 19 S p. S73
 artikel
283 PNS31 A VIA ADMINISTRATIVA COMO UMA ALTERNATIVA DE ACESSO AO MEDICAMENTO NO SISTEMA ÚNICO DE SAÚDE: SOLUÇÃO OU PROBLEMA? Messias, P.D.S.
 2019
 19 S p. S68
 artikel
284 PNS3 BRAZILIAN PHARMACEUTICAL INDUSTRY: THE IMPACT OF PUBLIC POLICIES AIMED AT FOSTERING LOCAL MANUFACTURING Boers Trilles, V.
 2019
 19 S p. S63
 artikel
285 PNS9 BUDGET IMPACT OF NEW RECOMMENDATION FOR ATROPINIZATION IN BRAZILIAN GUIDELINES FOR ANTICOLINESTARASIS INTOXICATION Vieira De Melo Junior, E.
 2019
 19 S p. S64
 artikel
286 PNS30 CHANGES IN THE OWNERSHIP STRUCTURE OF HUNGARIAN HEALTH CARE PROVIDERS Csákvári, T.
 2019
 19 S p. S68
 artikel
287 PNS29 CHANGING OF HEALTH CARE TOURISM AND ITS RECOVERING ROLE FOR ECONOMY Zoltán, V.
 2019
 19 S p. S67-S68
 artikel
288 PNS2 COLOMBIA'S HEALTHCARE REFORM: COST-CONTAINMENT MECHANISMS AND IMPLICATIONS FOR SUSTAINABILITY Boers Trilles, V.
 2019
 19 S p. S63
 artikel
289 PNS32 COMPARATIVE ANALYSIS OF TENDER LEGISLATION IN BRAZIL AND MEXICO Boers Trilles, V.
 2019
 19 S p. S68
 artikel
290 PNS34 COMPARING REMUNERATION OF GENERAL PRACTITIONERS IN COUNTRIES WITH BISMARCK- AND BEVERIDGE HEALTH CARE MODELS Elmer, D.
 2019
 19 S p. S68-S69
 artikel
291 PNS25 COMPARING THE REMUNERATION OF HOSPITAL NURSES IN COUNTRIES WITH BISMARCK AND BEVERIDGE HEALTH CARE SYSTEMS Elmer, D.
 2019
 19 S p. S67
 artikel
292 PNS44 COORDENAÇÃO DE CUIDADOS DE SAÚDE ATRAVÉS DE UM APLICATIVO MÓVEL COMO FATOR DE MELHOR RESULTADO CLÍNICO E REDUÇÃO DE CUSTOS Frighetto, G.
 2019
 19 S p. S71
 artikel
293 PNS22 DESCRIBING GAPS IN ACCESS TO HEALTHCARE BETWEEN INTERNATIONAL MIGRANTS AND THE CHILEAN-BORN POPULATION Moena, O.
 2019
 19 S p. S67
 artikel
294 PNS53 DESCRIPTION OF CLINICAL CHARACTERISTICS AND SELF REPORTED WILLINGNESS TO PAY FOR NEW TREATMENTS IN COLOMBIAN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS Hernandez, N.
 2019
 19 S p. S72-S73
 artikel
295 PNS15 DOES FOOD INSECURITY AFFECT PERFORMANCE AT SCHOOL? EVIDENCE FROM BRAZIL Wroblevski, B.
 2019
 19 S p. S65
 artikel
296 PNS21 EFECTIVIDAD DE INTERVENCIONES DE EDUCACION SEXUAL EN ADOLESCENTES: REVISION DE REVISIONES Garzón-Orjuela, N.
 2019
 19 S p. S66-S67
 artikel
297 PNS23 EPIDEMIOLOGY OF MYELOPROLIFERATIVE DISORDERS: REAL WORLD DATA STUDY IN BRAZIL Picoli, R.
 2019
 19 S p. S67
 artikel
298 PNS52 EQ-5D-5L SOCIAL VALUES IN PERU: A NOVEL "LITE” APPROACH Augustovski, F.
 2019
 19 S p. S72
 artikel
299 PNS56 ESTIMACIÓN DEL COSTO DOMICILIARIO EN LAS ALTAS TEMPRANAS PARA PACIENTES NO CRÓNICOS EN UNA RED INTEGRAL DE SALUD Romero Prada, M.
 2019
 19 S p. S73
 artikel
300 PNS43 ESTIMACIÓN DE UN COSTO DE REFERENCIA PARA EVENTOS HOSPITALARIOS MEDIANTE NORMALIZACIÓN DE DATOS Romero Prada, M.
 2019
 19 S p. S70-S71
 artikel
301 PNS14 EVIDENCE ON THE POSTPONEMENT OF MATERNITY IN BRAZIL Rosa, A.M.P.
 2019
 19 S p. S65
 artikel
302 PNS49 EVOLUTION AND RESULTS OF HEALTHCARE PERFORMANCE INDICATORS IN BRAZILIAN SELF-FUNDED HEALTH PLANS Mendes, L.H.
 2019
 19 S p. S72
 artikel
303 PNS1 ¿EXISTE SUFICIENTE EVIDENCIA PARA USAR SUPERVIVENCIA GLOBAL Y CALIDAD DE VIDA COMO DESENLACES CRÍTICOS EN LA TOMA DE DECISIONES EN SALUD? García Núncira, C.Y.
 2019
 19 S p. S63
 artikel
304 PNS11 FUNDING OF MANAGEMENT AND INCORPORATION OF TECHNOLOGIES IN BRAZILIAN HEALTH SYSTEM Vieira De Melo Junior, E.
 2019
 19 S p. S64-S65
 artikel
305 PNS24 GASTOS COM MEDICAMENTOS E SEU IMPACTO NA RENDA DAS FAMÍLIAS BRASILEIRAS Garcia, M.
 2019
 19 S p. S67
 artikel
306 PNS33 HEALTH PROTECTION POLICIES FOR INTERNATIONAL MIGRANTS IN AN IRREGULAR SITUATION: THE CASE OF CHILE Larenas-Rosa, D.
 2019
 19 S p. S68
 artikel
307 PNS18 HOW IS SELF-PERCEIVED HEALTH STATUS (EQ-5D) ASSOCIATED WITH PSYCHOSOCIAL FACTORS IN 22 LATIN AMERICAN COUNTRIES? Cabieses, B.
 2019
 19 S p. S66
 artikel
308 PNS39 HOW VALUE IS DEFINED BY DIFFERENT STAKEHOLDERS IN BRAZIL? Nita, M.E.
 2019
 19 S p. S69-S70
 artikel
309 PNS40 IMPACTO DE LA IMPLEMENTACIÓN DE UNA RED DE ATENCIÓN INTEGRADA EN SERVICIOS DE SALUD EN LA POBLACIÓN DEL NOROCCIDENTE COLOMBIANO Romero Prada, M.
 2019
 19 S p. S70
 artikel
310 PNS59 IMPACTO DEL MODELO DE RIESGO COMPARTIDO EN LA TASA DE EVENTOS HOSPITALARIOS DE UN SEGURO VOLUNTARIO EN COLOMBIA Romero Prada, M.
 2019
 19 S p. S73-S74
 artikel
311 PNS38 INVESTIGATING QUALITY AND PERFORMANCE INDICATORS RELATED TO OUTPATIENT CARE USING THE DELPHI METHOD Mendes, L.H.
 2019
 19 S p. S69
 artikel
312 PNS57 REAL WORLD EVIDENCE LANDSCAPE IN LATIN AMERICA HEALTH CARE DECISION MAKING: EXPLORING UNDERSTANDING, ACCEPTABILITY AND USE Hincapie, A.
 2019
 19 S p. S73
 artikel
313 PNS20 REPORTS OF SUBSTANDARD MEDICINES: AN ANALYSIS OF THE BRAZILIAN HEALTH SURVEILLANCE NOTIFICATION SYSTEM Fedalto, M.B.
 2019
 19 S p. S66
 artikel
314 PNS58 RESULTADOS DE UM PROGRAMA DE ATENDIMENTO EM SAÚDE EM ÁREAS REMOTAS DA AMAZÔNIA OCIDENTAL BRASILEIRA Azevedo, V.
 2019
 19 S p. S73
 artikel
315 PNS37 REVIEW OF QUALITY AND PERFORMANCE INDICATORS RELATED TO INPATIENT CARE IN SELF-FUNDED HEALTH PLANS Mendes, L.H.
 2019
 19 S p. S69
 artikel
316 PNS17 SELF-PERCEIVED DISCRIMINATION AMONG INTERNATIONAL MIGRANTS IN CHILE: RESULTS FROM A NATIONAL-BASED SURVEY (CASEN) 2017 Chepo, M.
 2019
 19 S p. S65-S66
 artikel
317 PNS35 THE EFFECT OF FINANCIAL INCENTIVE ON RETAINING DENTISTS IN RURAL AREAS IN THAILAND Noochpoung, R.
 2019
 19 S p. S69
 artikel
318 PNS12 THE IMPACT OF THE POSTPONEMENT OF MATERNITY ON WOMEN'S INCOME IN BRAZIL Andrade, J.L.
 2019
 19 S p. S65
 artikel
319 PNS10 THE PENALTY OF MATERNITY FOR LABOR MARKET IN BRAZIL Rosa, A.M.P.
 2019
 19 S p. S64
 artikel
320 PNS7 THE PRICE OF SUBSTITUTE TECHNOLOGIES Santos, A.
 2019
 19 S p. S64
 artikel
321 PNS4 TRENDS FOR INTRODUCTION OF APPROVED DRUGS IN NETWORK META-ANALYSIS Tonin, F.S.
 2019
 19 S p. S63-S64
 artikel
322 PNS36 TRENDS IN UNITED STATES EMERGENCY DEAPARTMENT VISITS AND CHARGES, 2010-2016 Mallow, P.
 2019
 19 S p. S69
 artikel
323 PNS48 USE OF REAL WORLD DATA FOR DEVELOPMENT OF AN ALGORITHM TO EVALUATE THE COMPLEXITY OF PEOPLE WITH CHRONIC DISEASES CONTROLLING FOR SOCIOECONOMIC AND ENVIRONMENTAL INEQUALITIES Franquet, Á.
 2019
 19 S p. S71-S72
 artikel
324 PNS6 VALUE-ASSESSMENT FRAMEWORKS: WE CANNOT ESCAPE THE ETHICAL DILEMMAS POSED BY THEIR USE Mallow, P.
 2019
 19 S p. S64
 artikel
325 PNS41 VALUE BASED HEALTH CARE (CUIDADO BASADO EM VALOR) EN AMERICA LATINA: RESULTADOS PRELIMINARES DE UNA INVESTIGACION CON 40 HOSPITALES DE CINCO PAISES LATINOAMERICANOS Makdisse, M.
 2019
 19 S p. S70
 artikel
326 PRO11 ANÁLISIS DE SERIE DE CASOS DE PACIENTES CON DIAGNÓSTICO DE HEMOFILIA A CON INHIBIDORES EN HOSPITALES DE ALTA COMPLEJIDAD EN ECUADOR Salgado, A.
 2019
 19 S p. S76
 artikel
327 PRO5 ASSESSMENT OF COST-EFFECTIVENESS RESULTS FROM ICER ADVANCED THERAPIES MEDICINAL PRODUCTS REVIEWS Arjunji, R.
 2019
 19 S p. S75
 artikel
328 PRO6 BURDEN OF ILLNESS OF SPINAL MUSCULAR ATROPHY TYPE 1 Droege, M.
 2019
 19 S p. S75
 artikel
329 PRO14 COMPARAR A INCIDÊNCIA DE COMORBIDADES NO TRATAMENTOS DE MIELOMA MÚLTIPLO ENTRE AS TERAPIAS DO SISTEMA DE SAÚDE BRASILEIRO (SUS) COM AS AINDA NÃO INCORPORADAS Ribeiro, A.
 2019
 19 S p. S76-S77
 artikel
330 PRO4 COST-EFFECTIVENESS ANALYSIS OF AN INTEGRATED EXTRACORPOREAL PHOTOPHERESIS SYSTEM VERSUS SELECTED TREATMENTS FOR REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE Okumura, L.
 2019
 19 S p. S74
 artikel
331 PRO3 DIRECT COSTS OF HEMOPHILIA CARE, THE CASE OF A HEALTH INSURER IN COLOMBIA Hoyos, F.
 2019
 19 S p. S74
 artikel
332 PRO10 EXPERIENCIA INTERNACIONAL EN EL USO DE ANÁLISIS DE DECISIÓN MULTICRITERIO (MCDA) PARA EVALUAR MEDICAMENTOS HUÉRFANOS: SCOPING REVIEW Lasalvia, P.
 2019
 19 S p. S75-S76
 artikel
333 PRO13 IMPACT OF CAREGIVER EXPERIENCE AND HRQOL IN LATER-ONSET SPINAL MUSCULAR ATROPHY (SMA): RESULTS FROM THE PHASE 3 CHERISH TRIAL Johnson, N.B.
 2019
 19 S p. S76
 artikel
334 PRO2 IMPACTO ORÇAMENTÁRIO DA IDURSULFASE NO TRATAMENTO DA MUCOPOLISSACARIDOSE TIPO 2 Vieira De Melo Junior, E.
 2019
 19 S p. S74
 artikel
335 PRO12 LITERATURE REVIEW OF CHALLENGES AND OPPORTUNITIES IN HEALTH ECONOMIC EVALUATION METHODOLOGY IN RARE DISEASES Decimoni, T.
 2019
 19 S p. S76
 artikel
336 PRO1 MEDICAL THERAPY FOR PULMONARY ARTERIAL HYPERTENSION (PAH): AN INDIRECT TREATMENT COMPARISON OF MACITENTAN AND BOSENTAN Di Scala, L.
 2019
 19 S p. S74
 artikel
337 PRO8 PROFILAXIS EN HEMOFILIA A CON INHIBIDORES EN COLOMBIA, ¿ES POSIBLE CONTAR CON TRATAMIENTOS QUE GENEREN AHORROS AL SISTEMA DE SALUD? Muñoz-Bedoya, A.
 2019
 19 S p. S75
 artikel
338 PRO9 PUBLIC PURCHASES OF ECULIZUMABE BY THE BRAZILIAN MINISTRY OF HEALTH: A PROFILE OF VOLUMES AND EXPENSES FROM 2007 TO 2018 Caetano, R.
 2019
 19 S p. S75
 artikel
339 PRS1 BUDGET IMPACT ANALYSIS OF UMECLIDINIUM VERSUS TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE Silva, D.
 2019
 19 S p. S77
 artikel
340 PRS2 COST ANALYSIS FOR THE TREATMENT OF SEVERE UNCONTROLLED BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION Yagudina, R.
 2019
 19 S p. S77
 artikel
341 PRS9 ESTIMATIVA DO CUSTO DA ASMA EM UM PLANO DE SAUDE NO BRASIL - ESTUDO DE MUNDO REAL Busch, J.
 2019
 19 S p. S78
 artikel
342 PRS8 HEALTH RESOURCE USE OF COPD PATIENTS IN THE BRAZILIAN PRIVATE HEALTHCARE SETTING Saturnino, L.T.M.
 2019
 19 S p. S78
 artikel
343 PRS4 HEALTH TECHNOLOGY ASSESSMENT OF DUPILUMAB IN SEVERE BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION Nedogoda, S.V.
 2019
 19 S p. S77
 artikel
344 PRS3 IDIOPATHIC PULMONARY FIBROSIS EXACERBATIONS : DIRECT COSTS OF MEDICAL RESOURCES Lew, D.
 2019
 19 S p. S77
 artikel
345 PRS6 LA EVOLUCIÓN DE LA CARGA DE ENFERMEDAD DE LA FIBROSIS PULMONAR IDIOPÁTICA EN LA POBLACIÓN ECUATORIANA DE 2011 A 2017 Villacres, T.
 2019
 19 S p. S77-S78
 artikel
346 PRS7 ¿REALMENTE ES UNA AMENAZA PARA LA SALUD DE LOS COLOMBIANOS? Hilarión-Gaitán, L.
 2019
 19 S p. S78
 artikel
347 PSU5 ANALISIS COSTE CONSECUENCIA DEL TRASPLANTE DE PROGENITORES HEMATOPOYETICOS DE DONANTE NO RELACIONADO FINANCIADO POR EL FONDO INTANGIBLE SOLIDARIO DE SALUD DEL PERU Flores Benites, V.
 2019
 19 S p. S79
 artikel
348 PSU4 BUDGET IMPACT ANALYSIS OF TRICLOSAN-COATED SUTURES FOR SURGICAL SITE INFECTION PREVENTION IN COLOMBIA Patino, A.F.
 2019
 19 S p. S79
 artikel
349 PSU7 COST-EFFECTIVENESS ANALYSIS OF APIXABAN FOR THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER HIP OR KNEE REPLACEMENT SURGERY IN COLOMBIA Castaño Gamboa, N.
 2019
 19 S p. S79
 artikel
350 PSU3 DETERMINACION DE CAMBIOS QUERATOMETRICOS POST QUIRURGICOS EN PACIENTES SOMETIDOS A PRK O LASIK MEDIANTE LASER EXCIMER VISX STAR S4IR Sepúlveda, F.
 2019
 19 S p. S78-S79
 artikel
351 PSU2 EFECTIVIDAD Y SEGURIDAD DEL USO DE LOS IMPLANTES DE AHMED, MOLTENO Y BAERVELDT EN PACIENTES OPERADOS CON GLAUCOMA CRONICO: UN META-ANALISIS EN RED Fau, C.
 2019
 19 S p. S78
 artikel
352 PSU6 ESTUDIO DE COSTO EFECTIVIDAD ENTRE HEPARINA NO FRACCIONADA Y HEPARINAS DE BAJO PESO MOLECULAR EN PACIENTES SOMETIDOS A ARTROPLASTIA TOTAL DE CADERA ELECTIVA Fau, C.
 2019
 19 S p. S79
 artikel
353 PSU8 IS HIP ARTHROSCOPY COST EFFECTIVE IN TREATING FEMOROACETABULAR IMPINGEMENT? A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS Weiss, O.
 2019
 19 S p. S80
 artikel
354 PSY11 ADESAO E CUSTOS ASSOCIADOS AO TRATAMENTO PROFILATICO DE PACIENTES HEMOFILICOS NO BRASIL Provin, M.
 2019
 19 S p. S82
 artikel
355 PSY4 BURDEN OF DISEASE FOR RHEUMATOID ARTHRITIS IN COLOMBIA AND BRAZIL Papadimitropoulos, M.
 2019
 19 S p. S80-S81
 artikel
356 PSY10 COST-EFFECTIVENESS ANALYSIS OF DRUG CHALLENGE TEST COMPARED TO SPECIFIC IGE DOSAGE FOR THE DIAGNOSIS OF PATIENTS WITH SUSPECT OF PENICILLIN ALLERGY dos Santos, W.M.
 2019
 19 S p. S82
 artikel
357 PSY8 CURRENT PRACTICE AND RESOURCE USE ASSOCIATED WITH TREATMENT OF VENOUS THROMBOEMBOLISM DISEASE IN SOCIAL SECURITY SECTOR OF ARGENTINA Albaytero, M.N.
 2019
 19 S p. S81-S82
 artikel
358 PSY6 HUMANISTIC AND ECONOMIC BURDEN OF DISEASE FOR PSORIASIS IN ARGENTINA, BRAZIL, COLOMBIA AND MEXICO Papadimitropoulos, M.
 2019
 19 S p. S81
 artikel
359 PSY9 PATRONES DE TRATAMIENTO FARMACOLOGICO EN PACIENTES ADULTOS CON DERMATITIS ATOPICA Machado Alba, J.
 2019
 19 S p. S82
 artikel
360 PSY5 QUALITY OF LIFE OF INDIVIDUALS WITH PSORIASIS IN LATIN AMERICA Papadimitropoulos, M.
 2019
 19 S p. S81
 artikel
361 PSY3 SECUKINUMAB VS ADALIMUMAB E INFLIXIMAB PARA EL TRATAMIENTO DE ESPONDILITIS ANQUILOSANTE: UN ANÁLISIS DE COSTO POR RESPONDEDOR A LA SEMANA 24 DESDE UNA PERSPECTIVA COLOMBIANA Afanador Echeverri, G.F.
 2019
 19 S p. S80
 artikel
362 PSY1 SECUKINUMAB VS ADALIMUMAB E INFLIXIMAB PARA EL TRATAMIENTO DE ESPONDILITIS ANQUILOSANTE: UN ANÁLISIS DE COSTO POR RESPONDEDOR A LA SEMANA 24 DESDE UNA PERSPECTIVA ECUATORIANA Afanador Echeverri, G.F.
 2019
 19 S p. S80
 artikel
363 PSY2 SECUKINUMAB VS ADALIMUMAB E INFLIXIMAB PARA EL TRATAMIENTO DE ESPONDILITIS ANQUILOSANTE: UN ANÁLISIS DE COSTO POR RESPONDEDOR A LA SEMANA 24 DESDE UNA PERSPECTIVA PERUANA Afanador Echeverri, G.F.
 2019
 19 S p. S80
 artikel
364 PSY7 VENOUS THROMBOEMBOLISM DISEASE: DIRECT COSTS ASSOCIATED WITH ITS TREATMENT IN ARGENTINA Elgart, J.
 2019
 19 S p. S81
 artikel
365 PUK7 ANALISIS DE EFECTIVIDAD Y SEGURIDAD DE MIRABEGRON EN PACIENTES CON SINDROME DE VEJIGA HIPERACTIVA Romero Prada, M.
 2019
 19 S p. S83
 artikel
366 PUK6 AN EVALUATION OF THE BRAZILIAN POLICY FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE UNDER THE PERSPECTIVE OF THE PUBLIC HEALTH CARE SYSTEM: WAS IT EFFECTIVE? Zanetti, I.
 2019
 19 S p. S83
 artikel
367 PUK1 COST CONSEQUENCE ANALYSIS OF A REMOTE MONITORING PROGRAM TO IMPROVE CLINICAL PRACTICE OF AUTOMATED PERITONEAL DYALISIS IN COLOMBIA Ariza, J.G.
 2019
 19 S p. S82
 artikel
368 PUK3 COST CONSEQUENCE ANALYSIS OF A REMOTE PATIENT MONITORING PROGRAM TO IMPROVE CLINICAL PRACTICE OF AUTOMATED PERITONEAL DYALISIS IN BRAZIL Gresse, S.
 2019
 19 S p. S82-S83
 artikel
369 PUK4 FACTORES ASOCIADOS DE LA PROGRESION DE LA ENFERMEDAD RENAL CRONICA EN UN PROGRAMA DE INTERVENCION DEL RIESGO CARDIOVASCULAR DEL CARIBE COLOMBIANO Miranda, P.A.
 2019
 19 S p. S83
 artikel
370 PUK5 POTENTIALLY INAPPROPRIATE PRESCRIPTIONS OF ANTICHOLINERGIC DRUGS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA Machado Alba, J.
 2019
 19 S p. S83
 artikel
371 RE2 Definiendo “Valor” en Latinoamérica: Lo bueno, lo malo y lo feo Alfonso-Cristancho, R.
 2019
 19 S p. S84
 artikel
372 RE4 PROPOSED SOLUTIONS TO ACHIEVING HEALTHCARE SUSTAINABILITY IN LATIN AMERICA Guarin, D.F.
 2019
 19 S p. S84-S85
 artikel
373 RE3 RELAPSING-REMITTING MULTIPLE SCLEROSIS: COSTS & BENEFITS OF EXPANDING COVERAGE FROM A PUBLIC PAYER PERSPECTIVE Lenz Alcayaga, R.
 2019
 19 S p. S84
 artikel
374 RE1 THE IMPACT OF REAL-WORLD EVIDENCE ON REIMBURSEMENT SUBMISSIONS: ARE WE CLEAR ON CURRENT PRACTICES? Barinova, A.
 2019
 19 S p. S84
 artikel
375 TP2 COSTS AND PRESCRIPTION PATTERN OF PATIENTS WITH PSORIATIC ARTHRITIS AND ITS ASSOCIATED COSTS Santos-Moreno, P.
 2019
 19 S p. S85
 artikel
376 TP3 Estudio de utilizacion de drogas: Descripción del uso de inmunoglobulina intravenosa humana en un Hospital Universitario de Bogotá, Colombia Correa Gonzalez, N.F.
 2019
 19 S p. S85
 artikel
377 TP4 REAL-WORLD PATIENT CHARACTERISTICS AND OUTCOMES OF RESECTED STAGE III MELANOMA PATIENTS IN ARGENTINA AND BRAZIL Villarroel, R.
 2019
 19 S p. S85
 artikel
378 TP1 TRATAMIENTO DEL CANCER DE MAMA ESTADIO IV, ANÃLISIS DE LOS DATOS REPORTADOS A LA CUENTA DE ALTO COSTO. COLOMBIA 2017 Choconta-Piraquive, L.A.
 2019
 19 S p. S85
 artikel
                             378 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland